Loss of HAT1 expression confers BRAFV600E inhibitor resistance to melanoma cells by activating MAPK signaling via IGF1R

BRAF inhibitors (BRAFi) have been approved for the clinical treatment of BRAF-mutant metastatic melanoma. Although initial responses to BRAFi are generally favorable, acquired BRAFi resistance emerges rapidly, resulting in treatment failure. Only some of the underlying mechanisms responsible for BRA...

Descripción completa

Detalles Bibliográficos
Autores principales: Bugide, Suresh, Parajuli, Keshab Raj, Chava, Suresh, Pattanayak, Rudradip, Manna, Deborah L. Della, Shrestha, Deepmala, Yang, Eddy S., Cai, Guoping, Johnson, Douglas B., Gupta, Romi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200761/
https://www.ncbi.nlm.nih.gov/pubmed/32371878
http://dx.doi.org/10.1038/s41389-020-0228-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200761/
https://www.ncbi.nlm.nih.gov/pubmed/32371878
http://dx.doi.org/10.1038/s41389-020-0228-x

Ejemplares similares